Literature DB >> 21941283

Rethinking ovarian cancer: recommendations for improving outcomes.

Sebastian Vaughan1, Jermaine I Coward, Robert C Bast, Andy Berchuck, Jonathan S Berek, James D Brenton, George Coukos, Christopher C Crum, Ronny Drapkin, Dariush Etemadmoghadam, Michael Friedlander, Hani Gabra, Stan B Kaye, Chris J Lord, Ernst Lengyel, Douglas A Levine, Iain A McNeish, Usha Menon, Gordon B Mills, Kenneth P Nephew, Amit M Oza, Anil K Sood, Euan A Stronach, Henning Walczak, David D Bowtell, Frances R Balkwill.   

Abstract

There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941283      PMCID: PMC3380637          DOI: 10.1038/nrc3144

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  82 in total

1.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

2.  The forgotten fallopian tube.

Authors:  Johannes Dietl; Jörg Wischhusen
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

Review 3.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

4.  IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Authors:  Michael S Anglesio; Joshy George; Hagen Kulbe; Michael Friedlander; Danny Rischin; Charlotte Lemech; Jeremy Power; Jermaine Coward; Prue A Cowin; Colin M House; Probir Chakravarty; Kylie L Gorringe; Ian G Campbell; Aikou Okamoto; Michael J Birrer; David G Huntsman; Anna de Fazio; Steve E Kalloger; Frances Balkwill; C Blake Gilks; David D Bowtell
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

Review 5.  Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Authors:  Adrian M Jubb; Adrian L Harris
Journal:  Lancet Oncol       Date:  2010-12       Impact factor: 41.316

6.  Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

Authors:  David M O'Malley; Debra L Richardson; Patrick S Rheaume; Ritu Salani; Eric L Eisenhauer; Georgia A McCann; Jeffrey M Fowler; Larry J Copeland; David E Cohn; Floor J Backes
Journal:  Gynecol Oncol       Date:  2011-02-18       Impact factor: 5.482

7.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Authors:  Alison M Karst; Keren Levanon; Ronny Drapkin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

8.  Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.

Authors:  Dariush Etemadmoghadam; Joshy George; Prue A Cowin; Carleen Cullinane; Maya Kansara; Kylie L Gorringe; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

9.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

Authors:  M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards
Journal:  Lancet       Date:  2010-12-21       Impact factor: 79.321

10.  Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.

Authors:  S L Cooke; J Temple; S Macarthur; M A Zahra; L T Tan; R A F Crawford; C K Y Ng; M Jimenez-Linan; E Sala; J D Brenton
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

View more
  519 in total

1.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

Review 2.  Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer.

Authors:  Shelley B Hooks; Mandi M Murph
Journal:  Future Med Chem       Date:  2015-08-21       Impact factor: 3.808

3.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

4.  Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.

Authors:  Kevin H Eng; Bret M Hanlon; William H Bradley; J Brian Szender
Journal:  Gynecol Oncol       Date:  2015-09-14       Impact factor: 5.482

5.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Authors:  Yi Kan Wang; Ali Bashashati; Michael S Anglesio; Dawn R Cochrane; Diljot S Grewal; Gavin Ha; Andrew McPherson; Hugo M Horlings; Janine Senz; Leah M Prentice; Anthony N Karnezis; Daniel Lai; Mohamed R Aniba; Allen W Zhang; Karey Shumansky; Celia Siu; Adrian Wan; Melissa K McConechy; Hector Li-Chang; Alicia Tone; Diane Provencher; Manon de Ladurantaye; Hubert Fleury; Aikou Okamoto; Satoshi Yanagida; Nozomu Yanaihara; Misato Saito; Andrew J Mungall; Richard Moore; Marco A Marra; C Blake Gilks; Anne-Marie Mes-Masson; Jessica N McAlpine; Samuel Aparicio; David G Huntsman; Sohrab P Shah
Journal:  Nat Genet       Date:  2017-04-24       Impact factor: 38.330

6.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

7.  High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors.

Authors:  Scott K Shaw; Cynthia L Schreiber; Felicia M Roland; Paul M Battles; Seamus P Brennan; Simon J Padanilam; Bradley D Smith
Journal:  Bioorg Med Chem       Date:  2018-03-06       Impact factor: 3.641

8.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

Review 9.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

10.  Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.

Authors:  Enrica Calura; Paolo Martini; Gabriele Sales; Luca Beltrame; Giovanna Chiorino; Maurizio D'Incalci; Sergio Marchini; Chiara Romualdi
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.